Back to news

Humana shares gain as investors digest raised outlook, fresh analyst target hikes, and debt tender launch

Investivoq PriceTracker

Humana Inc. (HUM) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued follow-through from Humana’s third-quarter report, where the company raised its full-year adjusted earnings outlook and posted better-than-expected operating metrics. Additional support may have come from a wave of higher analyst price targets after the report and from Humana’s new cash tender offers for outstanding senior notes, which can be read as active balance-sheet management.

Details:

  • Humana said on November 6 that it lifted 2026 adjusted EPS guidance to at least $9.50 from at least $9.00.
  • The company also disclosed a 3Q26 insurance benefit ratio of 93.7%, which it described as favorable to prior management guidance.
  • In the sessions following earnings, several Wall Street firms raised their price targets on the stock, including updates noted for JPMorgan, Deutsche Bank, Guggenheim, Piper Sandler, and Barclays.
  • Humana announced on November 9 that it commenced cash tender offers for certain outstanding senior notes, with an aggregate purchase cap of $1.5 billion.

    • Sources:

    Humana Investor Relations, SEC, StockAnalysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive HUM Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $HUM Hedge Fund Activity

    We have seen 514 institutional investors add shares of $HUM stock to their portfolio, and 403 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 3,234,637 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,284,862,509
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,370,831 shares (+inf%) to their portfolio in Q2 2026, for an estimated $544,521,489
    • ASSENAGON ASSET MANAGEMENT S.A. added 1,249,272 shares (+20126.8%) to their portfolio in Q3 2026, for an estimated $476,684,717
    • FMR LLC removed 964,170 shares (-33.1%) from their portfolio in Q3 2026, for an estimated $367,898,346
    • CAPITAL WORLD INVESTORS added 927,924 shares (+981.9%) to their portfolio in Q2 2026, for an estimated $368,589,971
    • INVESCO LTD. removed 907,025 shares (-38.0%) from their portfolio in Q2 2026, for an estimated $360,288,470
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 904,125 shares (-20.2%) from their portfolio in Q2 2026, for an estimated $359,136,532

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $HUM Price Targets

    Multiple analysts have issued price targets for $HUM recently. We have seen 11 analysts offer price targets for $HUM in the last 6 months, with a median target of $344.0.

    Here are some recent targets:

    • Ben Hendrix from RBC Capital set a target price of $415.0 on 07/09/2026
    • Sarah James from Cantor Fitzgerald set a target price of $300.0 on 07/07/2026
    • Kevin Fischbeck from B of A Securities set a target price of $380.0 on 06/24/2026
    • Elizabeth Suzuki from Evercore ISI Group set a target price of $370.0 on 06/11/2026
    • Lisa Gill from JP Morgan set a target price of $316.0 on 06/08/2026
    • Ann Hynes from Mizuho set a target price of $390.0 on 06/08/2026
    • Erin Wright from Morgan Stanley set a target price of $249.0 on 06/04/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.